MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Exploratory delayed-start analysis of PASADENA evaluating the efficacy of prasinezumab on motor progression and motor complications in early-stage Parkinson’s disease

G. Pagano, S. Zanigni, A. Monnet, K. Taylor, A. Hahn, T. Simuni, K. Marek, R. Postuma, N. Pavese, F. Stocchi, H. Svoboda, P. Fontoura, R. Doody, G. Kerchner, A. Bonni, T. Nikolcheva (Basel, Switzerland)

Meeting: 2022 International Congress

Abstract Number: 753

Keywords: Interventions, Parkinson’s, Scales

Category: Parkinson’s Disease: Clinical Trials

Objective: To evaluate the effect of prasinezumab on motor progression and motor complications in early-stage Parkinson’s disease (PD) using an exploratory delayed-start analysis of Part 2 (Week 104) of the Phase II PASADENA study (NCT03100149).

Background: Prasinezumab is a humanised monoclonal antibody designed to target aggregated α-synuclein and slow PD progression. PASADENA Part 1 did not meet the primary endpoint (Movement Disorders Society–Unified Parkinson’s disease Rating Scale [MDS-UPDRS] sum of Parts I+II+III); however, differences in MDS-UPDRS Part III scores suggest less motor progression in prasinezumab-treated participants than in the placebo group.

Method: Participants with early-stage PD (diagnosis ≤2 years at screening; Hoehn & Yahr Stages I–II) were randomised to receive intravenous prasinezumab every 4 weeks (1500 mg or 4500 mg) for 104 weeks (early-start group, n=204), or placebo for 52 weeks followed by prasinezumab (1500 mg or 4500 mg) for 52 weeks (delayed-start group, n=105). Participants were included in the analysis regardless of change in symptomatic therapy. Motor progression and motor complications were defined, respectively, as ≥5-point increase in MDS-UPDRS Part III and reaching a score of ≥1-point in MDS-UPDRS Part IV and analysed as time-to-event (TTE) using Cox proportional hazards models.

Results: Fewer participants in the early-start group (80.1%; median: 224 days) showed motor progression (reaching a ≥5-point increase in MDS-UPDRS Part III) (Figure 1) compared with the delayed-start group (89.5%; median: 169 days) (hazard ratio: 0.77 [80% CI 0.65–0.91]). Fewer participants in the early-start group (45.0%; median: 806 days) developed motor complications (reaching a score of ≥1-point in MDS-UPDRS Part IV) (Figure 2) compared with the delayed-start group (55.2%; median: 730 days) (hazard ratio: 0.74 [80% CI 0.60–0.92].

Conclusion: These findings suggest less motor progression and a lower risk of developing motor complications in early-stage PD participants treated with prasinezumab in the early-start group than in the delayed-start group.

Figure 1

Figure 2

To cite this abstract in AMA style:

G. Pagano, S. Zanigni, A. Monnet, K. Taylor, A. Hahn, T. Simuni, K. Marek, R. Postuma, N. Pavese, F. Stocchi, H. Svoboda, P. Fontoura, R. Doody, G. Kerchner, A. Bonni, T. Nikolcheva. Exploratory delayed-start analysis of PASADENA evaluating the efficacy of prasinezumab on motor progression and motor complications in early-stage Parkinson’s disease [abstract]. Mov Disord. 2022; 37 (suppl 2). https://www.mdsabstracts.org/abstract/exploratory-delayed-start-analysis-of-pasadena-evaluating-the-efficacy-of-prasinezumab-on-motor-progression-and-motor-complications-in-early-stage-parkinsons-disease/. Accessed July 6, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2022 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/exploratory-delayed-start-analysis-of-pasadena-evaluating-the-efficacy-of-prasinezumab-on-motor-progression-and-motor-complications-in-early-stage-parkinsons-disease/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Welcome to the MDS Abstracts Site
  • Life expectancy with and without Parkinson’s disease in the general population
  • Nilotinib for treating MSA: A preclinical proof of concept study
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley